With 7.41 million shares changed hands, the volume of the stock remained lighter than its average volume of 11.0 million shares. During the session, the Drug Manufacturers – General company that operates in wider Healthcare sector, reached to the highest price of $58.915 whereas the lowest price it dropped to was $57.62. The 52-week range on BMY shows that it touched its highest point at $61.08 and its lowest point at $39.35 during that stretch. It currently has a 1-year price target of $58.60. With its current market cap of 120.71 billion, BMY has annualized dividend of $2.40 while the current yield stands at 4.08%. BMY paid its most recent dividend on 1728000000, while the ex-dividend date for that was 1728000000. Beta for the stock currently stands at 0.45.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BMY was up-trending over the past week, with a rise of 4.71%, but this was up by 11.24% over a month. Three-month performance surged to 22.04% while six-month performance rose 42.75%. The stock gained 19.12% in the past year, while it has gained 14.73% so far this year. A look at the trailing 12-month EPS for BMY yields -3.60 with Next year EPS estimates of 7.06. For the next quarter, that number is 1.47. This implies an EPS growth rate of -88.13% for this year and 691.88% for next year. EPS is expected to decline by -3.30% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 5.14%.
Float and Shares Shorts:
At present, 2.03 billion BMY shares are outstanding with a float of 2.03 billion shares on hand for trading. On 2024-10-31, short shares totaled 23.42 million, which was 114.99999999999999 higher than short shares on 1727654400. In addition to Dr. Christopher S. Boerner Ph.D. as the firm’s CEO & Chairman, Mr. David V. Elkins serves as its Executive VP & CFO.
Institutional Ownership:
Through their ownership of 0.78406 of BMY’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, BMY reported revenue of $11892000000.0 and operating income of $2172000000.0. The EBITDA in the recently reported quarter was $5123000000.0 and diluted EPS was $0.6.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BMY since 14 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 9 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With BMY analysts setting a high price target of 73.0 and a low target of 39.0, the average target price over the next 12 months is 59.36909. Based on these targets, BMY could surge 24.0% to reach the target high and fall by -33.75% to reach the target low. Reaching the average price target will result in a growth of 0.85% from current levels.
Analysts have provided yearly estimates in a range of $1.05777 being high and $0.63662 being low. For BMY, this leads to a yearly average estimate of $0.89127. The surprise factor in the prior quarter was $1.63. Based on analyst estimates, the high estimate for the next quarter is $1.99 and the low estimate is $1.73. The average estimate for the next quarter is thus $1.85.
